Aoxing Pharmaceutical Company, Inc. Receives Audit Opinion With Going Concern Explanation
(firmenpresse) - JERSEY CITY, NJ -- (Marketwired) -- 10/03/14 -- Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN), a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management and addiction treatment pharmaceuticals, today announced that its audited consolidated financial statements for the fiscal year ended June 30, 2014, included in the Company''s Annual Report on Form 10-K, which was filed on September 29, 2014 with the Securities and Exchange Commission, contain an audit opinion from its independent registered public accounting firm that includes a going concern qualification.
This announcement is made pursuant to NYSE MKT Company Guide Section 610(b), which requires separate disclosure of receipt of an audit opinion containing a going concern qualification.
646-367-1747
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 03.10.2014 - 18:10 Uhr
Sprache: Deutsch
News-ID 1307384
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
JERSEY CITY, NJ
Phone:
Kategorie:
Drugs
Anmerkungen:
Diese Pressemitteilung wurde bisher 216 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Aoxing Pharmaceutical Company, Inc. Receives Audit Opinion With Going Concern Explanation
"
steht unter der journalistisch-redaktionellen Verantwortung von
Aoxing Pharmaceutical (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
